Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study

Study limitation reported by the research below: “The untreated cognitively impaired control group was assembled from a separate research registry (Knight ADRC), not a matched comparator arm, which may introduce selection bias.”